Fig. 5: Therapeutic effects of Mo-A and vancomycin against S. aureus USA300-induced pneumonia in mice. | npj Biofilms and Microbiomes

Fig. 5: Therapeutic effects of Mo-A and vancomycin against S. aureus USA300-induced pneumonia in mice.

From: Thwarting resistance: MgrA inhibition with methylophiopogonanone a unveils a new battlefront against S. aureus

Fig. 5

a Experimental model of MRSA-induced pneumonia in C57BL/6 J mice. b Checkerboard assay demonstrating the combined effects of Mo-A and vancomycin against S. aureus USA300. c The impact on survival rates of C57BL/6 J mice (n = 10) infected with a lethal dose of S. aureus USA300 treated with ΔmgrA, Mo-A, vancomycin, and their combination. d Mice were euthanized after 48 h, and lung tissue samples were collected to determine CFU per gram (n = 5). The results are presented as a scatter plot and median. e Lungs were grossly evaluated for all mice and histopathology of lung tissue from each group of mice (H&E staining). Scale bar of histopathology: 1 cm and scale bar of gross analysis: 50 μm. f–h Levels of the proinflammatory cytokines IL-1β, IL-6, and TNF-α in bronchoalveolar lavage fluid (n = 3). Data are presented as the mean ± standard deviation. The control group was treated with PBS group. *P < 0.05, **P < 0.01, ***P < 0.001 compared to USA300 (WT group).

Back to article page